Home・Akcijų sąrašas・TransMedics Group Inc

TransMedics Group Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

80.5 -1.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78.31

Max

81.92

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-98M 7.3M
Pardavimai	13M 174M
P/E Sektoriaus vid.	16.998 64.641
Pelnas, tenkantis vienai akcijai	0.3
Pelno marža	4.206
Darbuotojai	898
EBITDA	-4.9M 28M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+41.02% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-786M 2.6B
Ankstesnė atidarymo kaina	81.88
Ankstesnė uždarymo kaina	80.5

Naujienos nuotaikos

By Acuity

65%

35%

289 / 340 reitingas Healthcare

TransMedics Group Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-03 19:51; UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

2026-07-30 19:03; UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

2026-07-29 23:36; UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

2026-07-28 19:46; UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

2026-07-27 15:16; UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

2026-07-24 20:02; UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

2026-07-22 19:46; UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

2026-07-21 14:36; UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

2026-07-20 12:26; UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Akcijų palyginimas

Kainos pokytis

TransMedics Group Inc Prognozė

Kainos tikslas

By TipRanks

41.02% į viršų

12 mėnesių prognozė

Vidutinis 115 USD 41.02%

Aukščiausias 175 USD

Žemiausias 80 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines TransMedics Group Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių TransMedics Group Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

289 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.